South Korea
· Delayed Price · Currency is KRW LabGenomics Statistics
Total Valuation
LabGenomics has a market cap or net worth of KRW 228.29 billion. The enterprise value is 169.59 billion.
| Market Cap | 228.29B |
| Enterprise Value | 169.59B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LabGenomics has 74.24 million shares outstanding. The number of shares has increased by 4.81% in one year.
| Shares Outstanding | 74.24M |
| Shares Change (YoY) | +4.81% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 9.22% |
| Float | 61.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.67 |
| PB Ratio | 1.01 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.01 |
| EV / Sales | 1.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -12.97 |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 0.21.
| Current Ratio | 1.97 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.61 |
| Interest Coverage | -3.56 |
Financial Efficiency
Return on equity (ROE) is -9.32% and return on invested capital (ROIC) is -4.21%.
| Return on Equity (ROE) | -9.32% |
| Return on Assets (ROA) | -3.79% |
| Return on Capital (ROIC) | -4.21% |
| Revenue Per Employee | 458.82M |
| Profits Per Employee | -113.84M |
| Employee Count | 186 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 26.82 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.56% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -27.56% |
| 50-Day Moving Average | 3,239.70 |
| 200-Day Moving Average | 3,088.50 |
| Relative Strength Index (RSI) | 48.18 |
| Average Volume (20 Days) | 9,377,899 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LabGenomics had revenue of KRW 85.34 billion and -21.17 billion in losses. Loss per share was -285.28.
| Revenue | 85.34B |
| Gross Profit | 30.15B |
| Operating Income | -18.77B |
| Pretax Income | -23.75B |
| Net Income | -21.17B |
| EBITDA | -10.36B |
| EBIT | -18.77B |
| Loss Per Share | -285.28 |
Balance Sheet
The company has 105.95 billion in cash and 47.25 billion in debt, giving a net cash position of 58.70 billion or 790.68 per share.
| Cash & Cash Equivalents | 105.95B |
| Total Debt | 47.25B |
| Net Cash | 58.70B |
| Net Cash Per Share | 790.68 |
| Equity (Book Value) | 225.71B |
| Book Value Per Share | 3,040.26 |
| Working Capital | 73.63B |
Cash Flow
In the last 12 months, operating cash flow was -9.84 billion and capital expenditures -3.23 billion, giving a free cash flow of -13.08 billion.
| Operating Cash Flow | -9.84B |
| Capital Expenditures | -3.23B |
| Free Cash Flow | -13.08B |
| FCF Per Share | -176.14 |
Margins
Gross margin is 35.33%, with operating and profit margins of -22.00% and -24.81%.
| Gross Margin | 35.33% |
| Operating Margin | -22.00% |
| Pretax Margin | -27.82% |
| Profit Margin | -24.81% |
| EBITDA Margin | -12.14% |
| EBIT Margin | -22.00% |
| FCF Margin | -15.32% |
Dividends & Yields
LabGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.81% |
| Shareholder Yield | -4.81% |
| Earnings Yield | -9.28% |
| FCF Yield | -5.73% |
Stock Splits
The last stock split was on August 7, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Aug 7, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
LabGenomics has an Altman Z-Score of 3.22.
| Altman Z-Score | 3.22 |
| Piotroski F-Score | n/a |